• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Viemed Healthcare Inc. (Amendment)

    2/15/24 9:27:58 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care
    Get the next $VMD alert in real time by email
    SC 13D/A 1 sc13dmmoore-021524.htm SC 13D/A Document

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

    SCHEDULE 13D
    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2(a)
    (Amendment No. 2)1

    Viemed Healthcare, Inc.
    (Name of Issuer)

    Common Shares, No Par Value
    (Title of Class of Securities)

    92663R105
    (CUSIP Number)
    Michael Moore
    625 E. Kaliste Saloom Rd.
    Lafayette, Louisiana 70508
    (337) 504-3802
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    February 15, 2024
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box: ☐
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
    1The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    1


    1.
    NAMES OF REPORTING PERSONS    

    Michael Moore
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)☐
    (b)☐
    3.SEC USE ONLY
    4.
    SOURCE OF FUNDS (SEE INSTRUCTIONS) OO
    5.CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
    6.
    CITIZENSHIP OR PLACE OF ORGANIZATION    United States
    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH
    7.SOLE VOTING POWER798,304
    8.SHARED VOTING POWER1,722,614
    9.SOLE DISPOSITIVE POWER798,304
    10.SHARED DISPOSITIVE POWER1,722,614
    11.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    2,520,918 shares of Common Stock
    12.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (SEE INSTRUCTIONS)
        ☐
    13.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    6.5%2
    14.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)    IN
    2Assumes 38,756,636 Common Shares of the Company outstanding as of February 15, 2024 based on information provided by the Issuer.
    2


    1.
    NAMES OF REPORTING PERSONS    

    Moore Faster LLC
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)☐
    (b)☐
    3.SEC USE ONLY
    4.
    SOURCE OF FUNDS (SEE INSTRUCTIONS) OO
    5.CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
    6.
    CITIZENSHIP OR PLACE OF ORGANIZATION    Louisiana
    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH
    7.SOLE VOTING POWER0
    8.SHARED VOTING POWER1,722,614
    9.SOLE DISPOSITIVE POWER0
    10.SHARED DISPOSITIVE POWER1,722,614
    11.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,722,614 shares of Common Stock
    12.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (SEE INSTRUCTIONS)
        ☐
    13.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    4.4%3
    14.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)    OO (Limited Liability Company)
    3 Assumes 38,756,636 Common Shares of the Company outstanding as of February 15, 2024 based on information provided by the Issuer.
    3


    Item 1.        Security and Issuer.

    This Amendment No. 2 (“Amendment No. 2”) amends the Schedule 13D initially filed on February 12, 2021, as amended on May 18, 2023 (collectively, the “Schedule 13D”), and is filed to report changes in the beneficial ownership of Common Shares by Michael Moore. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

    Item 2. Identity and Background.

    Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    a. This Schedule 13D is filed by Michael Moore, a natural person (“Moore”), and Moore Faster LLC, a Louisiana limited liability company (“MF LLC”) (collectively, the “Reporting Persons”).

    b.The business address of Moore is 625 E. Kaliste Saloom Rd, Lafayette, Louisiana 70508 and the business address of MF LLC is 625 E. Kaliste Saloom Rd, Lafayette, Louisiana 70508.

    c.As of February 15, 2024, Moore is employed as the President by the Issuer, and the principal business of MF LLC is to invest in securities and other assets.

    d.During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    e.During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order (i) enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or (ii) finding a violation with respect to such laws.

    f.Moore is a citizen of the United States of America and MF LLC is a Louisiana limited liability company.

    Item 4. Identity and Background.

    Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    Each of the Reporting Persons holds the Shares as reported herein for investment purposes and does not have any specific plans or proposals regarding the Issuer in such Reporting Person’s capacity as a holder of Common Shares. Each of the Reporting Persons does not have any current plans or proposals which relate to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D.

    Item 5.        Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:


    4


    (a) – (b)
    The percent of class provided for the Reporting Persons is made in accordance with Rule 13d-3(d) of the Securities Act of 1933, as amended (the “Securities Act”) and is based on 38,756,636 Common Shares outstanding as of February 15, 2024 based on information provided by the Issuer. Moore is the beneficial owner of 2,520,918 Common Shares, which amount includes 1,722,614 shares held by MF LLC and 671,962 shares issuable upon the exercise of options that are vested or will vest within 60 days. Moore has the sole power to vote or to direct the vote of and the sole power to dispose of or to direct the disposition of 798,304 Common Shares. Each of Moore and MF LLC shares the power to vote or to direct the vote of or to dispose or to direct the disposition of 1,722,614 Common Shares. Moore owns 50% of the ownership units in MF LLC and serves as a general manager of MF LLC.

    The information provided on the cover pages with respect to the beneficial ownership of Moore is incorporated herein by reference.

    (c)On January 4, 2021, an award of 99,243 restricted share units granted to Moore vested, which entitled Moore with the right to receive one Common Share per restricted stock unit. The Issuer withheld 30,917 Common Shares to satisfy Moore’s tax obligation resulting from the vesting of the 99,243 restricted share units.

    On January 4, 2021, an award of 43,513 stock options awards granted to Moore vested.

    On January 17, 2021, an award of 121,299 stock options awards granted to Moore vested.

    On January 21, 2021, Moore received a grant of 120,584 options to acquire Common Shares under the 2020 Incentive Plan, which award vests in three equal annual installments beginning on the first anniversary of the grant date.

    On January 17, 2022, an award of 121,299 stock options awards granted to Moore vested.

    On January 18, 2022, Moore received a grant of 85,410 options to acquire Common Shares and 56,937 restricted stock units under the 2020 Incentive Plan, which award vests in three equal annual installments beginning on the first anniversary of the grant date.
    5


    On January 21, 2022, an award of 40,195 stock options awards granted to Moore vested.

    On January 17, 2023, Moore received a grant of 80,818 restricted stock units under the 2020 Incentive Plan, which award vests in three equal annual installments beginning on the first anniversary of the grant date.

    On January 17, 2023, an award of 52,224 stock options awards granted to Moore vested.

    On January 18, 2023, an award of 28,470 stock options awards granted to Moore vested and an award of 18,979 restricted share units granted to Moore vested which entitled Moore with the right to receive one Common Share per restricted stock unit. The Issuer withheld 6,767 Common Shares to satisfy Moore’s tax obligation resulting from the vesting of the 18,979 restricted share units.

    On January 21, 2023, an award of 40,195 stock options awards granted to Moore vested.

    On August 14, 2023, Moore transferred 1,722,614 Common Shares to MF LLC for estate planning purposes.

    On January 17, 2024, an award of 26,939 restricted share units granted to Moore vested, which entitled Moore with the right to receive one Common Share per restricted stock unit. The Issuer withheld 9,223 Common Shares to satisfy Moore’s tax obligation resulting from the vesting of the 26,939 restricted share units.

    On January 18, 2024, an award of 28,470 stock options awards granted to Moore vested and an award of 18,979 restricted share units granted to Moore vested which entitled Moore with the right to receive one Common Share per restricted stock unit. The Issuer withheld 5,761 Common Shares to satisfy Moore’s tax obligation resulting from the vesting of the 18,979 restricted share units.

    On January 21, 2024, an award of 40,195 stock options awards granted to Moore vested.

    On January 29, 2024, Moore received a grant of 80,527 restricted stock units under the 2020 Incentive Plan, which award vests in three equal annual installments beginning on the first anniversary of the grant date.
      
    (d) – (e)Not applicable




    Item 7. Material to be Filed as Exhibits.

    The following exhibit is added to the exhibits listed in Item 7 of the Schedule 13D:


    99.1 Joint Filing Agreement dated as of February 15, 2024 among the Reporting Persons.

    6


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 15, 2024



    /s/ Michael Moore
    Michael Moore


    Moore Faster LLC

    /s/ Michael Moore
    Michael Moore, General Manager

    7


    Exhibit 99.1

    JOINT FILING AGREEMENT

    The undersigned hereby agree that the statement on Schedule 13D with respect to the shares of common stock of Viemed Healthcare, Inc. dated as of February 15, 2024 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.


    /s/ Michael Moore
    Michael Moore

    Moore Faster LLC

    /s/ Michael Moore
    Michael Moore, General Manager
    8
    Get the next $VMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VMD

    DatePrice TargetRatingAnalyst
    11/3/2021$13.00 → $9.00Outperform
    RBC Capital
    More analyst ratings

    $VMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viemed Healthcare Announces Share Repurchase Program

    LAFAYETTE, La., June 09, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that its Board of Directors has authorized a share repurchase program, effective through June 2026. Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company ("the Common Shares") from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding Common Shares as of March 31, 2025. The Company intends to repurchase Common Shares through open market purchases, block purchases o

    6/9/25 8:00:00 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare to Present and Host 1x1 Investor Meetings at the 15th Annual East Coast Ideas Investor Conference on June 11th in New York

    LAFAYETTE, La., June 03, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced it will present at the East Coast IDEAS Investor Conference on Wednesday June 11, 2025 at The Westin Times Square in New York, NY. Viemed's presentation is scheduled to begin at 11:30am ET. The presentation is webcast and can be accessed through the conference host's main website: https://www.threepartadvisors.com/east-coast and in the investor relations section of the Company's website: http://viemed.com/investors. ABOUT VIEMED HEALTHCARE, INC. Viemed is an

    6/3/25 8:00:00 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Announces First Quarter 2025 Financial Results

    LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

    5/7/25 4:45:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital reiterated coverage on Viemed Healthcare with a new price target

    RBC Capital reiterated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

    11/3/21 9:01:34 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Royal Bank of Canada initiated coverage on Viemed Healthcare with a new price target

    Royal Bank of Canada initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

    3/11/21 8:08:09 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    RBC Capital initiated coverage on Viemed Healthcare with a new price target

    RBC Capital initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

    3/5/21 8:11:16 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $VMD
    SEC Filings

    View All

    Heltz Sabrina bought $19,977 worth of shares (2,820 units at $7.08), increasing direct ownership by 7% to 41,040 units (SEC Form 4)

    4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

    5/14/24 5:25:11 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    SEC Form S-8 filed by Viemed Healthcare Inc.

    S-8 - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

    8/12/25 4:39:52 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by Viemed Healthcare Inc.

    10-Q - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

    8/6/25 5:06:51 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

    8/6/25 5:04:31 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaushal Nitin converted options into 15,732 shares, increasing direct ownership by 12% to 142,575 units (SEC Form 4)

    4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

    8/20/25 6:22:41 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Director Smokoff Timothy converted options into 15,732 shares, increasing direct ownership by 20% to 95,518 units (SEC Form 4)

    4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

    8/20/25 6:22:15 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Director Dobbs Randy E. converted options into 17,784 shares, increasing direct ownership by 17% to 125,490 units (SEC Form 4)

    4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

    8/20/25 6:20:37 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Leadership Updates

    Live Leadership Updates

    View All

    Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois

    LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment ("Lehan"), a healthcare company offering home medical equipment with specialties in respiratory care and women's health. "Operating for nearly 80 years, Lehan has established a well-deserved reputation for its expertise in home medical equipment with a particular emphasis on women's health and a deep commitment to community engagement," said Viemed Chief

    5/6/25 8:30:00 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

    LAFAYETTE, La., April 02, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health ("EAH"), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to patients within the EAH network as well as those in the surrounding areas of Eastern Alabama. "We are thrilled to join forces with the exceptional team at East Alabama Health to deliver best-in-class home medical services to their patients and expand Home

    4/2/24 9:00:00 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Announces Voting Results From Its Annual General Meeting of Shareholders

    LAFAYETTE, La., June 13, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD, TSX:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced the voting results from its annual general meeting of shareholders held on June 13, 2023 (the "Meeting") in Lafayette, Louisiana. The total number of shares represented in person or by proxy at the Meeting was 27,309,147, representing 71.33% of the total issued and outstanding shares in the capital of the Company. Election of Directors The eight candidates nominated for election to the Company's Board of Directors (the "Board") and listed in the Company's m

    6/13/23 5:00:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Viemed Healthcare Inc. (Amendment)

    SC 13D/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

    2/15/24 9:27:58 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Viemed Healthcare Inc. (Amendment)

    SC 13G/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

    2/15/24 9:27:32 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by Viemed Healthcare Inc.

    SC 13G - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

    2/14/24 4:51:42 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Financials

    Live finance-specific insights

    View All

    Viemed Healthcare Announces First Quarter 2025 Financial Results

    LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

    5/7/25 4:45:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Announces First Quarter 2025 Earnings Conference Call Details

    LAFAYETTE, La., April 22, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (866) 682-6100 (US Toll-Free) +1 (862) 298-0702 (International) Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=0dOJVhdb Following the live call, a replay will be available in the Investor Relations section of the Company's website at www.viemed.com. ABOUT VIE

    4/22/25 4:30:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Announces Record 2024 Financial Results

    LAFAYETTE, La., March 10, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months and year ended December 31, 2024, and issued its guidance for the full year ending December 31, 2025. Fourth Quarter and Full Year Operational Highlights (all dollar amounts are USD): Net revenues for the quarter ended December 31, 2024 reached a new Company record of $60.7 million representing an increase of $10.0 million, or 20%, over net revenues reported for the comparable quarter ended Decembe

    3/10/25 5:00:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care